Gynäkologische Endokrinologie

, Volume 2, Issue 1, pp 27–32 | Cite as

Zur Genetik und Pathogenese des Uterus myomatosus

Leitthema

Zusammenfassung

Eine Beziehung zwischen dem Leiomyomwachstum und dem hormonellen Status der Patientinnen ist eindeutig zu erkennen, aber ein Zusammenhang zwischen der Ätiologie des Uterus myomatosus und der Steroidhormone als Ursache des Tumorwachstums ist nicht erwiesen. Möglicherweise regen Östrogen und Progesteron die Proliferation der Myome durch Aktivierung von Protoonkogenen und Wachstumsfaktoren an. Das familiäre Auftreten der Myome ist durch Keimzellmutationen im Fumarathydrogenase-Gen auf dem Chromosom 1 bedingt. Zahlreiche zytogenetisch erfassbare chromosomale Aberrationen finden sich im Myom mit einer Präferenz für die Chromosomen 12 und 7. Da nur ein Teil der uterinen Myome Aberrationen des Chromosomensatzes aufweist, kommt dies als allgemeine Ursache nicht in Frage . Die Aberrationen könnten lediglich ein sekundäres Phänomen in diesem Typus eines benignen Tumors darstellen, jedoch mit Auswirkungen z. B. auf das Wachstumspotenzial des Tumors. Die Microarray-Technik stellt ein neues Werkzeug dar, um die Gene zu erfassen, die in den Leiomyomen des Uterus hoch- bzw. runterreguliert werden.

Schlüsselwörter

Uterus myomatosus Chromosomenaberration Genregulation Keimzellmutation Microarray 

Genetics and pathogenesis of uterine leiomyoma

Abstract

A time-related correlation between the growth of uterine leiomyomata and hormonal status is evident; however, a causative correlation of the etiology of uterine leiomyoma and steroid hormones has not yet been demonstrated. Estrogen and progesterone may mediate the proliferation of the fibroids by activating protooncogenes and growth factors. Germline mutations in the fumarate hydratase gene located on chromosome 1 predispose to uterine fibroids. A number of different chromosomal aberrations are found in many uterine fibroids, preferentially involving chromosomes 12 and 7. These aberrations have to be considered a secondary phenomena rather than causative, though they may stimulate the growth potential of the tumor. Microarray technology represents a new tool for identifying genes responsible for up- or downregulation of genes related to the development of leiomyomata.

Keywords

Uterine leiomyoma Chromosomal aberration Gene regulation Steroid hormone effects Germ cell mutation Microarray 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Literatur

  1. 1.
    Algadir A (2003) Uterusmyome. Ätiologische Faktoren und Rezeptorverhalten. Dissertationschrift. Martin-Luther-Universität Halle-WittenbergGoogle Scholar
  2. 2.
    Amant F, Huys E, Geurts-Moespot A et al. (2003) Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. J Soc Gynecol Investig 10:105–109CrossRefPubMedGoogle Scholar
  3. 3.
    Andersen J (1996) Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol 14:269–282PubMedGoogle Scholar
  4. 4.
    Baird D, Dunson DB, Hill MC et al. (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107CrossRefPubMedGoogle Scholar
  5. 5.
    Catherino WH, Segars JH (2003) Microarray analysis in fibroids: which gene list is the correct list? Fertil Steril 80:293–294CrossRefPubMedGoogle Scholar
  6. 6.
    Dallenbach-Hellweg, Dietel M (1997) Weibliches Genitale. In: Remmele W (Hrsg) Pathologie, Bd. 4. Springe, Berlin Heidelberg New York Tokyo, S 1–131Google Scholar
  7. 7.
    Freije WA (2003) Genome biology and gynecology: the application of oligonucleotide microarrays to leiomyomata. Fertil Steril 80:277–278CrossRefPubMedGoogle Scholar
  8. 8.
    Garman ME, Blumberg MA, Ernst R, Raimer SS (2003) Familial leiomyomatosis: a review and discussion of pathogenesis. Dermatol 207:210–213CrossRefGoogle Scholar
  9. 9.
    Hennig Y, Deichert U, Bonk U et al. (1999) Chromosomal translocation affecting 12q14–15 but not deletions of the long arm of chromosome 7 associated with a growth advantage of uterine smooth muscle cells. Mol Hum Reprod 5:1150–1154CrossRefPubMedGoogle Scholar
  10. 10.
    Hsieh YY, Chang CC, Tsai FJ et al. (2003) Estrogen receptor thymidine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma. Fertil Steril 79:96–99CrossRefPubMedGoogle Scholar
  11. 11.
    Hu J, Surti U (1991) Subgroups of uterine leiomyomas based on cytogenetic analysis. Hum Pathol 22:1009–1016PubMedGoogle Scholar
  12. 12.
    Kjerulff KH, Langenberg P, Seidman JD et al. (1996) Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 41:483–490PubMedGoogle Scholar
  13. 13.
    Lehtonen R, Kiuru M, Vanharanta S et al. (2004) Bilallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164:17–22PubMedGoogle Scholar
  14. 14.
    Marshall LM, Spiegelman D, Barbieri RL et al. (1997) Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90:967–973CrossRefPubMedGoogle Scholar
  15. 15.
    Martinez-Mir A, Glaser B, Chuang GS et al. (2003) Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata. J Invest Dermatol 121:741–744CrossRefPubMedGoogle Scholar
  16. 16.
    Mine N, Kurose K, Nagai H et al. (2001) Gene fusion involving HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet 46:408–412CrossRefPubMedGoogle Scholar
  17. 17.
    Mitelman F, Johansson B, Mertens F (2003) Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/MitelmanGoogle Scholar
  18. 18.
    Moran C, Murillo HA, de la Cruz SI et al. (1998) Uterine leiomyomatosus in the female in late menopause. Ginecol Obst Mex 66:358–361Google Scholar
  19. 19.
    Nilbert M, Heim S, Mandahl N et al. (1989) Different karyotypic abnormalities, t(1;6) and del(7), in two uterine leiomyomas from the same patient. Cancer Genet Cytogenet 42:51–53CrossRefPubMedGoogle Scholar
  20. 20.
    Nilbert M, Heim S (1990) Uterine leiomyomata cytogenetics. Genes Chromosomes Cancer 2:3–13PubMedGoogle Scholar
  21. 21.
    Roth TM, Gustilo-Ashby T, Barber MD, Myers ER (2003) Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol 101:881–884CrossRefPubMedGoogle Scholar
  22. 22.
    Sadan O, van Iddekinge B, Savage N et al. (1988) Ethnic variation in estrogen and progesterone receptor concentration in leiomyoma and normal myometrium. Gynecol Endocrinol 2:275–282PubMedGoogle Scholar
  23. 23.
    Patrikis MI, Bryan EJ, Thomas NA et al. (2003) Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. Mol Carcinog 37:61–64CrossRefPubMedGoogle Scholar
  24. 24.
    Piva M, Flieger O, Rider V (1996) Growth fator control of cultured rat uterine stromal proliferation is progesterone dependent. Biol Reprod 55:1333–1342PubMedGoogle Scholar
  25. 25.
    Rein MS (2002) Advances in uterine leiomyoma research: the progesterone hypothesis. Eviron Health Perspect 108 [Suppl 5]:791–793Google Scholar
  26. 26.
    Rein MS, Powell WL, Walters FC et al. (1998) Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 4:83–86CrossRefPubMedGoogle Scholar
  27. 27.
    Tomlinson IP, Alam NA, Rowan AJ et al. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410PubMedGoogle Scholar
  28. 28.
    Tsibris JC, Segars J, Coppola D et al. (2002) Insights in gene arrays in the development and growth regulation of uterine leiomyomata. Fertil Steril 78:114–121CrossRefPubMedGoogle Scholar
  29. 29.
    Tsibris JC, Segars J, Enkemann S et al. (2003) Fertil Steril 80:279–281CrossRefPubMedGoogle Scholar
  30. 30.
    Vanni R, Nieddu M, Paoli R, Lecca U (1989) Uterine leiomyoma cytogenetics. I. Rearrangements of chromosme 12. Cancer Genet Cytogenet 37:49–54CrossRefPubMedGoogle Scholar
  31. 31.
    Virchow R (1854) Über Makroglossie und pathologische Neubildung quergestreifter Muskelfasern. Virchow Arch Pathol Anat 7:126–138Google Scholar
  32. 32.
    Wang H, Mahadevappa M, Yamamoto K et al. (2003) Distinctive proliferative pahse differences in gene expression in human myometrium and leiomyomata. Fertil Steril 80:266–276CrossRefPubMedGoogle Scholar
  33. 33.
    Wanschura S, Kazmierczak B, Schoenmakers E et al. (1996) Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma, and pleomorphic adenoma of the salivary gland to 12q15. Genes Chromosome Cancer 15:195–196Google Scholar
  34. 34.
    Wisot AL, Neimand KM, Rosenthal AH (1969) Symptomatic myoma in a 13-year-old girl. Am J Obstet Gynecol 105:639–641PubMedGoogle Scholar
  35. 35.
    Wu X, Wang H, Englund K et al. (2002) Expression of progesterone receptors A and B and insulin-like growth factor-I in human myometrium and fibroids after treatment with a gonadotropin-releasing hormone analogue. Fertil Steril 78:985–993CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Institut für PathologieUniversität zu LübeckLübeck
  2. 2.Institut für PathologieUniversität zu LübeckLübeck

Personalised recommendations